降压药物及联合方案的不良反应与停药:网络荟萃分析
结果显示钙通道阻滞剂(CCB)、ACEI联合CCB及β受体阻滞剂联合噻嗪类利尿剂较安慰剂显著增加停药,而含血管紧张素Ⅱ受体阻滞剂(ARB)方案停药少于安慰剂。
要点
- CCB、ACEI+CCB、β受体阻滞剂+噻嗪类因不良事件停药风险高于安慰剂。
- ARB单药及ARB+CCB因不良事件停药风险低于安慰剂。
- 所有方案均增加头晕,除CCB外均减少头痛。
核心结论
- 短期降压治疗因不良事件停药的风险因药物类别和方案而异,部分联合方案耐受性优于单药。
- 含ARB方案停药少于安慰剂,提示总体症状改善。
研究设计与样本
- 采用固定效应网络荟萃分析,报告OR及95%可信区间(CrI)。
主要发现
- 与安慰剂相比,CCB因不良事件停药OR为1.43(95%CrI 1.23-1.67),风险差1.2%。
- ACEI+CCB停药OR为1.46(95%CrI 1.13-1.87),风险差1.1%。
- β受体阻滞剂+噻嗪类停药OR为1.58(95%CrI 1.04-2.47),风险差1.7%。
- ARB单药停药OR为0.73(95%CrI 0.61-0.86),风险差-0.8%。
- ARB+CCB停药OR为0.61(95%CrI 0.47-0.79),风险差-1.2%。
关键数值与推荐
- 主要结局为因不良事件停药。
- 次要结局包括头痛、头晕、水肿和咳嗽。
- 所有方案均显著增加头晕,除CCB外均显著减少头痛。
临床怎么用
- 选择降压方案时可参考药物类别及联合方案对因不良事件停药风险的影响。
- 对耐受性敏感的患者,含ARB方案可能减少因不良事件停药。
局限性
- 基于试验水平结果,依赖网络荟萃分析假设。
- 结果可能不适用于个体患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Adverse drug effects from blood pressure (BP)-lowering drugs contribute to significant undertreatment and poor overall BP control rates. OBJECTIVE: To review adverse effects and discontinuation of BP-lowering drugs and their combinations from the 5 major classes in short-term clinical trials. DATA SOURCES AND STUDY SELECTION: Cochrane Central Register of Controlled Trials for randomized clinical trials, MEDLINE, and Epistemonikos were searched from the date of inception until December 31, 2024, for double-blind randomized clinical trials of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers (ARBs), β-blockers, calcium channel blockers (CCBs), thiazide and thiazide-like diuretics, or their combinations, with follow-up durations between 4 and 26 weeks. DATA EXTRACTION AND SYNTHESIS: Data extraction was performed by 2 independent reviewers. Synthesis was performed using fixed-effect network meta-analyses according to drug class, summarized using odds ratios (ORs) and 95% credible intervals (CrIs) and surface under the cumulative ranking curves. Final statistical analysis was conducted in April 2026. MAIN OUTCOMES AND MEASURES: Treatment discontinuation due to adverse events (AEs), defined as discontinuation of randomized treatment due to an AE. Secondary outcomes included headache, dizziness, edema, and cough. RESULTS: A total of 716 trials were included, with mean (SD) follow-up of 8.6 (5) weeks, including 159 362 participants (mean [SD] age, 54.6 [7] years; 44% female; mean baseline BP, 158/100 mm Hg). Compared with placebo, treatment discontinuation due to AEs was significantly increased by CCBs (OR, 1.43 [95% CrI, 1.23-1.67]; risk difference [RD], 1.2% [95% CrI, 0.6%-2.0%]), angiotensin-converting enzyme inhibitors plus CCBs (OR, 1.46 [95% CrI, 1.13-1.87]; RD, 1.1% [95% CrI, 0.2%-2.4%]), and β-blockers plus thiazide diuretics (OR, 1.58 [95% CrI, 1.04-2.47]; RD, 1.7% [95% CrI, 0.1%-4.3%]). All ARB-containing regimens had fewer treatment discontinuations due to AEs than placebo, and these differences were statistically significant for ARB monotherapy (OR, 0.73 [95% CrI, 0.61-0.86]; RD, -0.8% [95% CrI, -1.3% to -0.4%]) and ARBs plus CCBs (OR, 0.61 [95% CrI, 0.47-0.79]; RD, -1.2% [95% CrI, -1.8% to -0.6%]). In network meta-analyses, 5 combination and 2 monotherapy regimens had higher surface under the cumulative ranking curve values than placebo for treatment discontinuation due to AEs, suggesting overall symptomatic improvement compared with placebo. All regimens significantly increased dizziness, and all but CCBs significantly decreased headache compared with placebo. CONCLUSIONS AND RELEVANCE: This meta-analysis of short-term randomized clinical trials found that adverse drug effects that led to discontinuation of BP-lowering therapy varied by drug class and regimen, with several combination therapies being better tolerated than monotherapies. Some regimens were associated with fewer drug withdrawals than placebo, suggesting a net symptomatic improvement. These findings are based on trial-level results and rely on assumptions underlying the network meta-analysis; they may not apply to individual patients.
引用
- Wang N, Van Der Hoorn S, Pant R, et al. Adverse Effects and Treatment Discontinuation of Blood Pressure-Lowering Drugs and Combinations: A Network Meta-Analysis. JAMA. 2026. PMID: 42207501. doi:10.1001/jama.2026.6214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。